Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

'Blinding' involves concealing knowledge of which trial participants received the interventions from participants themselves and other trial personnel throughout the trial. Blinding reduces bias arising from the beliefs and expectations of these groups. It is agreed that where possible, blinding should be attempted, for example by ensuring that experimental and control treatments look the same. However, there is a debate about if we should measure whether blinding has been successful, this manuscript will discuss this controversy, including the benefits and risks of measuring blinding within the randomised controlled trial.

Original publication

DOI

10.1016/j.jclinepi.2021.02.022

Type

Journal article

Journal

J clin epidemiol

Publication Date

07/2021

Volume

135

Pages

176 - 181

Keywords

Blinding, Masking, Measuring, Reporting guidelines, Trials, Clinical Trials as Topic, Double-Blind Method, Humans, Placebo Effect, Placebos, Research Design, Single-Blind Method